Currently Approved Prophylactic HPV Vaccines

Diane M Harper


Expert Rev Vaccines. 2009;8(12):1663-1679. 

In This Article

Five-year View

It is highly likely that the prophylactic vaccines will be found to be effective at preventing autoinoculation of HPV infections in women already actively infected with HPV. These data are being collected over longer follow-up times than the initial pivotal trials. This would broaden the use of HPV vaccines to infected women and potentially older women to help stem the secondary outbreaks of similar anogenital cancers 10–20 years after the first CIN 3 development.

There is already a supplemental vaccine being trialed for Gardasil recipients that is hypothesized to provide protection against the HPV types for which it does not currently have cross-protection (HPV-31, -33, -45, -52 and -58). The long-term plan is to combine the current four HPV types in Gardasil with these supplemental five oncogenic HPV types to broaden the cancer protection possible for Gardasil. When Merck will withdraw Gardasil for its replacement nonovalent vaccine is unknown.

Therapeutic vaccines have been slower to develop than the prophylactic vaccines. Developing a vaccine whose primary method of action is the cell-mediated immune response with killer T cells actively destroying HPV-infected epithelial cells has been technically more challenging. Several candidate vaccines are in early trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: